Brainomix is a technology company.
Brainomix has raised $53.0M across 5 funding rounds.
Brainomix has raised $53.0M in total across 5 funding rounds.
Brainomix has raised $53.0M in total across 5 funding rounds.
Brainomix's investors include Boehringer Ingelheim Venture Fund, Parkwalk Advisors.
Brainomix is a medical software company specializing in AI-powered imaging biomarkers for precision medicine, primarily targeting stroke and lung fibrosis. It develops the Brainomix 360 platform, including tools like e-Stroke and e-Lung, which analyze brain and lung scans in real-time to support clinicians in making faster, more accurate treatment decisions—such as identifying stroke patients eligible for mechanical thrombectomy or predicting lung fibrosis progression.[1][2][3][4][6] Serving hospitals, stroke networks, and physicians worldwide, Brainomix addresses critical delays in diagnosis and treatment, where patients lose millions of brain cells per minute during strokes; its FDA-cleared and CE-marked solutions have boosted thrombectomy rates by over 50% in real-world use, benefiting over 1.5 million patients across 300+ hospitals in 20+ countries.[3][5][6][7] Recent momentum includes a £14M ($18M) Series C funding round in 2024 to expand its transformative AI tech, nationwide deployments in Wales and Hungary, and partnerships like with Boehringer Ingelheim.[3][7]
Founded in 2010 as a spin-out from the University of Oxford's Nuffield Department of Clinical Neurosciences, Brainomix emerged from research in AI-driven medical imaging to improve stroke diagnosis.[1][3][4][5][9] Dr. Michalis Papadakis, the CEO and co-founder, leads the company, drawing on Oxford's scientific expertise to pioneer tools like the e-Stroke platform for real-time CT scan analysis of brain damage.[4] Early traction came from award-winning biomarkers that enabled remote access to imaging data, evolving from stroke focus to include lung fibrosis with FDA-cleared e-Lung tech; pivotal moments include NICE endorsement, global expansion to the US and 20+ countries, and clinical studies validating impact, such as tripling functional independence rates at sites like Royal Berkshire Hospital.[3][5][7][8]
Brainomix rides the AI in precision medicine wave, particularly in neuroimaging and chronic disease prediction, amid rising stroke incidence (global leader in thrombectomy AI) and demand for scalable diagnostics post-COVID.[3][7][8] Timing aligns with regulatory progress (FDA/CE clearances) and health system pressures for efficiency, as AI bridges radiologist shortages and enables thrombectomy expansion to late-window patients, influencing ecosystems via nationwide rollouts (e.g., all Welsh/Hungarian stroke centers) and media validation from NHS leaders.[5][7][8] It shapes stroke care by standardizing decisions, boosting outcomes, and extending to lung fibrosis, fostering AI adoption in public health systems and attracting healthtech investors.[3][9]
Brainomix is poised for accelerated US growth post-Series C, with e-Lung partnerships potentially mirroring stroke success in fibrosis markets, while expanding AI biomarkers to other conditions.[3][9] Trends like real-world evidence mandates, AI-healthcare integration, and value-based care will propel it, evolving its influence from stroke pioneer to multi-disease platform leader—ultimately saving more lives through precision decisions, as its Oxford roots continue driving global impact.[1][3][7]
Brainomix has raised $53.0M across 5 funding rounds. Most recently, it raised $18.0M Series C in March 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2025 | $18.0M Series C | Boehringer Ingelheim Venture Fund, Parkwalk Advisors | |
| Dec 1, 2021 | $21.0M Series B | Boehringer Ingelheim Venture Fund, Parkwalk Advisors | |
| Apr 1, 2018 | $10.0M Venture Round | Boehringer Ingelheim Venture Fund, Parkwalk Advisors | |
| Oct 1, 2016 | $2.0M Series B | Boehringer Ingelheim Venture Fund, Parkwalk Advisors | |
| Sep 1, 2014 | $2.0M Series A | Boehringer Ingelheim Venture Fund, Parkwalk Advisors |